Trial NCT01193491

View at ClinicalTrials.gov 
Org. Study IDs: IPI-493-02

Last trial update was posted on 2015-04-15

MeSH Interventions

Geldanamycin

MeSH Conditions

Hematologic Neoplasms Neoplasms

Other Conditions

Hematologic Malignancies

Stopping Reasons

Drug exposure of retaspimycin HCl was superior to IPI-493, Infinity will focus on Retaspimycin HCL

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID